New drug discovery - Zydus Lifesciences Ltd

Code BSE: 532321 NSE:

Zydus’ new drug discovery, ‘Desidustat’ licensed to China Medical System Holdings receives approval from NMPA of China Desidustat tablets are administered orally and represent a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients. CKD involves the gradual loss of kidney function and eventually leads to kidney failure. Healthy kidneys naturally secrete a hormone called Erythropoietin (EPO), which stimulates red blood cell production, also known as erythropoiesis. When kidneys are impaired in patients with Chronic Kidney Disease, EPO production is reduced, leading to the development of anaemia. HIF-PHI promotes erythropoiesis by increasing endogenous erythropoietin, reducing hepcidin thereby improving iron availability.